Delving into the Latest Updates on Phrixus Pharmaceuticals, Inc. with Synapse

概览

关联

1

项与 Phrixus Pharmaceuticals, Inc. 相关的临床试验

NCT03558958

/ Terminated临床2期

An Exploratory, Open-label Study to Assess the Effect of P-188 NF (Carmeseal-MD) on Safety, on Respiratory and Cardiac Dysfunction and on Upper Limb Strength in Non-ambulatory Patients With Duchenne Muscular Dystrophy (DMD)

This is an open-label study to evaluate the safety, tolerability and efficacy of daily, subcutaneous dosing with P-188 NF (Carmeseal-MD™) in non-ambulatory boys with Duchenne Muscular Dystrophy (DMD). This study will determine if continuous treatment with Carmeseal-MD™ can maintain or improve pulmonary function, and skeletal and cardiac muscle function, compared to baseline, in boys 12-25 years of age.

开始日期2018-08-08

申办/合作机构

Phrixus Pharmaceuticals, Inc.

[+1]

100 项与 Phrixus Pharmaceuticals, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Phrixus Pharmaceuticals, Inc. 相关的专利（医药）

登录后查看更多信息

100 项与 Phrixus Pharmaceuticals, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Phrixus Pharmaceuticals, Inc. 相关的转化医学

登录后查看更多信息